Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.10 AUD
115.22 M AUD
212.98 M AUD
53.08 M
About Pro Medicus, Ltd.
Sector
Industry
CEO
Sam Aaron Hupert
Website
Headquarters
Richmond
Founded
1983
ISIN
AU000000PME8
FIGI
BBG000C41NB3
Pro Medicus Ltd. engages in the development and supply of healthcare imaging software, Radiology Information System (RIS), and services to hospitals. It operates through the following geographical segments: Australia, Europe, and North America. The firm’s products include Visage 7 and Visage RIS. The company was founded by Sam Aaron Hupert and Anthony Barry Hall in 1983 and is headquartered in Richmond, Australia.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PME is 308.29 AUD — it has decreased by −0.05% in the past 24 hours. Watch Pro Medicus, Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange Pro Medicus, Ltd. stocks are traded under the ticker PME.
PME stock has fallen by −4.50% compared to the previous week, the month change is a 0.53% rise, over the last year Pro Medicus, Ltd. has showed a 76.76% increase.
We've gathered analysts' opinions on Pro Medicus, Ltd. future price: according to them, PME price has a max estimate of 350.00 AUD and a min estimate of 225.65 AUD. Watch PME chart and read a more detailed Pro Medicus, Ltd. stock forecast: see what analysts think of Pro Medicus, Ltd. and suggest that you do with its stocks.
PME stock is 2.85% volatile and has beta coefficient of 1.62. Track Pro Medicus, Ltd. stock price on the chart and check out the list of the most volatile stocks — is Pro Medicus, Ltd. there?
Today Pro Medicus, Ltd. has the market capitalization of 31.52 B, it has increased by 2.86% over the last week.
Yes, you can track Pro Medicus, Ltd. financials in yearly and quarterly reports right on TradingView.
Pro Medicus, Ltd. is going to release the next earnings report on Feb 17, 2026. Keep track of upcoming events with our Earnings Calendar.
PME earnings for the last half-year are 0.61 AUD per share, whereas the estimation was 0.58 AUD, resulting in a 4.38% surprise. The estimated earnings for the next half-year are 0.69 AUD per share. See more details about Pro Medicus, Ltd. earnings.
Pro Medicus, Ltd. revenue for the last half-year amounts to 115.75 M AUD, despite the estimated figure of 115.78 M AUD. In the next half-year revenue is expected to reach 134.46 M AUD.
PME net income for the last half-year is 63.47 M AUD, while the previous report showed 51.74 M AUD of net income which accounts for 22.66% change. Track more Pro Medicus, Ltd. financial stats to get the full picture.
Pro Medicus, Ltd. dividend yield was 0.19% in 2025, and payout ratio reached 49.87%. The year before the numbers were 0.28% and 50.46% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 30, 2025, the company has 132 employees. See our rating of the largest employees — is Pro Medicus, Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Pro Medicus, Ltd. EBITDA is 164.93 M AUD, and current EBITDA margin is 77.44%. See more stats in Pro Medicus, Ltd. financial statements.
Like other stocks, PME shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Pro Medicus, Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Pro Medicus, Ltd. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Pro Medicus, Ltd. stock shows the buy signal. See more of Pro Medicus, Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.